Case report of penile cancer recurrence treated with cetuximab combined with anlotinib
- PMID: 35223013
- PMCID: PMC8847399
- DOI: 10.1002/ccr3.5443
Case report of penile cancer recurrence treated with cetuximab combined with anlotinib
Abstract
Penile squamous cell carcinoma with pelvic lymph node metastases/recurrence has a poor prognosis. We reported a case with recurrent pSCC was administered cetuximab and anlotinib after failure of first-line treatment and achieved an effective response. Cetuximab combined with anlotinib may be a new choice for relapsed pSCC.
Keywords: chemotherapy; metastases; penial squamous cell carcinoma; recurrence; targeted therapy.
© 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
Conflict of interest statement
The author reports no conflict of interest in this work.
Figures



Similar articles
-
Multimodal Treatment Combining Salvage Surgery-Assisted Chemotherapy and Checkpoints Blockade Immunotherapy Achieves Complete Remission on a Recurrent Penile Cancer Patient: A Case Report.Onco Targets Ther. 2021 Sep 22;14:4891-4896. doi: 10.2147/OTT.S319932. eCollection 2021. Onco Targets Ther. 2021. PMID: 34588783 Free PMC article.
-
Case report of penile squamous cell carcinoma continuous treatment with BRCA2 mutation.World J Surg Oncol. 2024 Feb 9;22(1):50. doi: 10.1186/s12957-024-03305-9. World J Surg Oncol. 2024. PMID: 38336701 Free PMC article.
-
Immune landscape and immunotherapy for penile cancer.Front Immunol. 2022 Nov 29;13:1055235. doi: 10.3389/fimmu.2022.1055235. eCollection 2022. Front Immunol. 2022. PMID: 36524123 Free PMC article. Review.
-
Cetuximab and paclitaxel combination therapy for recurrent basaloid squamous cell carcinoma in the ethmoid sinus.Auris Nasus Larynx. 2021 Dec;48(6):1189-1192. doi: 10.1016/j.anl.2020.07.002. Epub 2020 Jul 16. Auris Nasus Larynx. 2021. PMID: 32684403
-
Management of Advanced Penile Cancer.Mayo Clin Proc. 2021 Mar;96(3):720-732. doi: 10.1016/j.mayocp.2020.06.031. Epub 2020 Dec 9. Mayo Clin Proc. 2021. PMID: 33308870 Review.
Cited by
-
Evidence-Based Recommendations on the Use of Immunotherapies and Monoclonal Antibodies in the Treatment of Male Reproductive Cancers.Curr Oncol. 2025 Feb 14;32(2):108. doi: 10.3390/curroncol32020108. Curr Oncol. 2025. PMID: 39996908 Free PMC article. Review.
References
Publication types
LinkOut - more resources
Full Text Sources